Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1986 1
1988 1
1989 4
1990 2
1991 2
1992 1
1994 3
1995 4
1996 2
1997 8
1998 6
1999 6
2000 8
2001 9
2002 7
2003 10
2004 16
2005 20
2006 17
2007 15
2008 15
2009 23
2010 16
2011 22
2012 20
2013 19
2014 26
2015 18
2016 19
2017 20
2018 23
2019 32
2020 24
2021 34
2022 24
Text availability
Article attribute
Article type
Publication date

Search Results

430 results
Results by year
Filters applied: . Clear all
Page 1
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. Doroshow DB, et al. Among authors: rimm dl. Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. doi: 10.1038/s41571-021-00473-5. Epub 2021 Feb 12. Nat Rev Clin Oncol. 2021. PMID: 33580222 Review.
PD-L1 Expression in Lung Cancer.
Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR. Yu H, et al. Among authors: rimm dl. J Thorac Oncol. 2016 Jul;11(7):964-75. doi: 10.1016/j.jtho.2016.04.014. Epub 2016 Apr 23. J Thorac Oncol. 2016. PMID: 27117833 Free PMC article. Review.
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.
Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Wang J, et al. Among authors: rimm dl. Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4. Nat Med. 2019. PMID: 30833750 Free PMC article.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Doroshow DB, et al. Among authors: rimm dl. Clin Cancer Res. 2019 Aug 1;25(15):4592-4602. doi: 10.1158/1078-0432.CCR-18-1538. Epub 2019 Mar 1. Clin Cancer Res. 2019. PMID: 30824587 Free PMC article. Review.
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Berry S, Giraldo NA, Green BF, Cottrell TR, Stein JE, Engle EL, Xu H, Ogurtsova A, Roberts C, Wang D, Nguyen P, Zhu Q, Soto-Diaz S, Loyola J, Sander IB, Wong PF, Jessel S, Doyle J, Signer D, Wilton R, Roskes JS, Eminizer M, Park S, Sunshine JC, Jaffee EM, Baras A, De Marzo AM, Topalian SL, Kluger H, Cope L, Lipson EJ, Danilova L, Anders RA, Rimm DL, Pardoll DM, Szalay AS, Taube JM. Berry S, et al. Among authors: rimm dl. Science. 2021 Jun 11;372(6547):eaba2609. doi: 10.1126/science.aba2609. Science. 2021. PMID: 34112666 Free PMC article.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. Salgado R, et al. Among authors: rimm dl. Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11. Ann Oncol. 2015. PMID: 25214542 Free PMC article.
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. El Bairi K, et al. Among authors: rimm dl. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. NPJ Breast Cancer. 2021. PMID: 34853355 Free PMC article. Review.
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Nielsen TO, et al. Among authors: rimm dl. J Natl Cancer Inst. 2021 Jul 1;113(7):808-819. doi: 10.1093/jnci/djaa201. J Natl Cancer Inst. 2021. PMID: 33369635 Free PMC article.
Immunological differences between primary and metastatic breast cancer.
Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. Szekely B, et al. Among authors: rimm dl. Ann Oncol. 2018 Nov 1;29(11):2232-2239. doi: 10.1093/annonc/mdy399. Ann Oncol. 2018. PMID: 30203045 Free article.
430 results